Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NETWORK 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Breast Neoplasms 3Endometrial Neoplasms 2Breast Carcinoma In Situ 2Vitamin D Deficiency 1Polycystic Ovary Syndrome 1Paget's Disease, Mammary 1Kidney Neoplasms 1Hot Flashes 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Intraductal, Noninfiltrating 1Carcinoma, Ductal, Breast 1

Interventions

Cisplatin 3Taxes 2Paclitaxel 2Doxorubicin 2trastuzumab biosimilar HLX02 1trametinib 1pegfilgrastim 1nintedanib 1cediranib 1brivanib 1Trastuzumab 1Sunitinib 1Radiotherapy, Intensity-Modulated 1Radiotherapy 1Radiation 1Platinum 1PF-05280014 1Ontruzant 1Ogivri 1Medroxyprogesterone Acetate 1Medroxyprogesterone 1MK 2206 1Laparoscopy 1Immunoglobulin G 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1GSK2141795 1Filgrastim 1Disulfides 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Endometrial Adenocarcinoma × Medroxyprogesterone × Clear all
NCT00064025 2016-04-11

Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus

GOG Foundation

Phase 2 Completed
75 enrolled 6 charts
Gynecologic

Endometrial Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡